Charles River Laboratories International Inc., founded in 1947 and headquartered in Wilmington, Massachusetts, is a leading provider of comprehensive preclinical and clinical laboratory services for the global pharmaceutical, biotechnology, and medical device industries. The company specializes in drug discovery and development, offering a wide range of services including early-stage research, laboratory services, and support for toxicology and efficacy studies.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| CRL 3.75% 2029-03-15 USDCharles River Laboratories International Inc. | United States | 2029-03-15 | 3.750 | 5.09 |
| CRL 3.75% 2029-03-15 USDCharles River Laboratories International Inc. | United States | 2029-03-15 | 3.750 | 5.22 |
| CRL 4.00% 2031-03-15 USDCharles River Laboratories International Inc. | United States | 2031-03-15 | 4.000 | 5.26 |
| CRL 4.00% 2031-03-15 USDCharles River Laboratories International Inc. | United States | 2031-03-15 | 4.000 | 5.29 |
| CRL 4.25% 2028-05-01 USDCharles River Laboratories International Inc. | United States | 2028-05-01 | 4.250 | 4.84 |
| CRL 4.25% 2028-05-01 USDCharles River Laboratories International Inc. | United States | 2028-05-01 | 4.250 | 4.84 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Charles River began issuing bonds in 2018 to finance expansions and acquisitions, with a notable $500 million offering to fund strategic growth initiatives in 2020. As of now, the yield on their bonds is competitive, reflecting strong demand in the market, and their recent issuance in 2022 featured a 10-year maturity with favorable terms. Notably, the bond proceeds have facilitated significant infrastructure improvements, enhancing their operational capabilities, and supporting a growing portfolio of services in the biotechnology sector.